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Abstract
Background: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a systemic autoimmune
disease characterized by destructive vascular inflammation. Two prominent ANCA autoantigens are myeloperoxidase
(MPO) and proteinase 3 (PR3), and transcription of MPO and PRTN3, the genes encoding the autoantigens, is associated
with disease activity. We investigated whether patients with AAV have alterations in histone modifications, particularly
those associated with transcriptional activation, at MPO and PRTN3.
Results: We identified a network of genes regulating histone modifications that were differentially expressed in AAV
patients compared to healthy controls. We focused on four genes (EHMT1 and EHMT2, ING4, and MSL1) and found their
expression correlated with expression of MPO and PRTN3. Methylation of histone H3K9, catalyzed by EHMT1 and
EHMT2 and associated with gene silencing, was most depleted at MPO and PRTN3 in patients with active disease and
the highest MPO and PRTN3 expression. Acetylation of histone H4K16, modified by complexes containing ING4 and
MSL1 and associated with gene activation, was most enriched at MPO and PRTN3 in patients with active disease and
the highest MPO and PRTN3 expression. Methylation at H3K4, a mark of transcriptional activation, was enriched at MPO
and PRTN3 in patients and healthy controls.
Conclusions: MPO and PRTN3 in neutrophils of AAV patients with active disease have a distinct pattern of histone
modifications, which implicates epigenetic mechanisms in regulating expression of autoantigen genes and suggests
that the epigenome may be involved in AAV pathogenesis.
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Background
Anti-neutrophil cytoplasmic autoantibody (ANCA)-asso-
ciated small-vessel vasculitis is an autoimmune disease
characterized by autoantibodies directed against neutro-
phil granule proteins myeloperoxidase (MPO) or protein-
ase 3 (PR3). In vitro assays and in vivo mouse models
have established a pathogenic role for MPO-ANCA and
suggest that PR3-ANCA is pathogenic [1–4]. Despite
these data, the correlation of ANCA titers and disease
status is less than perfect, with reports of 25 % of pa-
tients having no relationship between clinical status
and presence of ANCA [5]. In addition, naturally oc-
curring autoantibodies to MPO in healthy individuals
[6, 7] and multi-specific ANCA in ulcerative colitis
[8] suggest that the characteristic vascular pathology
requires additional component(s) beyond disrupted
immunological tolerance to self. A prime candidate
responsible for the pathology in patients with AAV is
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the neutrophil. Neutrophils are the major sources of
PR3 and MPO, and vascular damage results from
ANCA binding to these autoantigens inducing de-
granulation of primed neutrophils [1, 9–12]. This raises
the question of whether neutrophils from healthy individ-
uals compared to patients with AAV differ in a molecular
signature, which could indicate a mechanism for neutro-
phil dysregulation in AAV.
A specific feature of mature peripheral blood neutro-
phils in patients with AAV is the presence of mRNA for
PRTN3 and MPO [13]. Normally, these genes are tran-
scribed in neutrophil progenitors residing in the bone
marrow [14]. To explain the observation of aberrant
autoantigen expression in AAV, we proposed that per-
ipheral blood neutrophils from patients with AAV fail to
silence or maintain silencing of PRTN3 and MPO due to
reduced levels of the epigenetic modification histone H3
lysine 27 trimethylation (H3K27me3), associated with
transcriptionally silent chromatin [15]. We hypothesize
that in neutrophils of patients with AAV, a pattern of
histone modifications at PRTN3 and MPO genes, in-
cluding histone modifications associated with tran-
scriptional activation, is associated with disease status,
but which ones are altered among the myriad possi-
bilities is unknown.
We probed expression data from AAV patients and
healthy individuals to identify differentially expressed
genes that encode proteins responsible for histone modi-
fications associated with transcriptional activity. We de-
termined whether the levels of histone modifications at
PRTN3 and MPO differed between AAV patients and
healthy individuals. Interestingly, measuring the levels of
several histone modifications at PRTN3 and MPO
revealed an epigenetic signature that is related to gene
expression and AAV disease status.
Results
Analysis of microarray expression data to identify genes
that regulate chromatin modifications
Previous studies demonstrated that MPO and PRTN3
transcripts are aberrantly elevated in patients with AAV
compared to healthy controls, and their expression levels
are highly correlated [13]. Later, epigenetic differences
were identified in patients with AAV and the transcrip-
tional regulation of MPO and PRTN3 involved epigen-
etic control [15]. To identify additional epigenetic
mechanisms that may be faulty in patients with AAV, we
analyzed microarray expression data from 25 peripheral
blood leukocyte samples of AAV patients and 16 sam-
ples from healthy controls (Additional file 1: Table S1).
We found 11,444 genes to be differentially regulated (≥
± 1.2-fold and p < 0.05) in AAV patients. Principal com-
ponent analysis (PCA) revealed the gene expression pro-
files in AAV patients cluster separately from expression
profiles of healthy controls (Fig. 1a). The list of differen-
tially expressed genes was filtered using Ingenuity Path-
way Analysis (IPA) to identify genes associated with
chromatin modifications. Among these were genes in-
volved in controlling epigenetic marks of transcriptional
activation and transcriptional silencing (Table 1). IPA
also revealed that 30 of these genes were involved in a
network with connections to histone, histone H3 and/or
histone H4 (Fig. 1b). This discovery of differentially
expressed genes responsible for regulatory histone modi-
fications warranted further investigation of epigenetic
mechanisms in AAV patients.
Expression of histone modifying genes
From our filtered list of differentially expressed genes,
we evaluated two genes (Euchromatic histone-lysine N-
methyltransferase 1 and 2, EHMT1/GLP and EHMT2/
Fig. 1 Bioinformatic analysis of microarray gene expression data
comparing leukocytes from AAV patients to healthy controls. a Principal
component analysis of the gene expression profile is shown for AAV
patients, represented by red dots, and for healthy controls, represented
by blue dots. b Gene expression data was processed with Ingenuity
Pathway Analysis software to unveil biological networks. The primary
network shown is for genes with functional annotations related to
histone, histone H3, and/or histone H4. Genes with increased or
decreased expression in AAV patients compared to healthy controls are
shown in red and green, respectively
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G9a) that regulate histone H3K9 methylation, associated
with transcriptionally silent chromatin, and two genes
(male sex lethal 1 homolog, MSL1 and insulin growth
factor, ING4) that regulate histone acetylation, associated
with transcriptionally active chromatin. We chose
EHMT1/GLP and EHMT2/G9a to address whether the
H3K9me2 pathway was involved in epigenetic silencing
of MPO and PRTN3 expression. We investigated genes
that regulate histone acetylation as a mechanistic ex-
planation for increased expression of MPO and PRTN3
in patients with AAV. MSL1 is a subunit of a human
acetyltransferase (HAT) complex that acetylates histone
H4K16 [16]. ING4 plays a complex role in gene regula-
tion [17]. It associates with HBO1 HAT complex [18],
but ING4 can also interact with NFkB and enhance
HDAC-1 levels at promoters [19]. Microarray analysis
revealed expression of EHMT1/GLP, and EHMT2/G9a
was significantly depleted in leukocytes from AAV pa-
tients compared to healthy controls, while expression of
MSL1 was statistically elevated (Table 1). Interestingly,
leukocytes from AAV patients had reduced ING4 ex-
pression compared to healthy controls. Expression levels
of EHMT2/G9a and ING4 negatively and MSL1 posi-
tively correlated with PRTN3 and MPO mRNA levels
(Table 2). EHMT1/GLP did not show a significant
correlation with PRTN3 and MPO mRNA.
Quantitative RT-PCR (qRT-PCR), to confirm the
microarray results, was used to measure mRNA levels
for MPO, PRTN3, EHMT1 and 2, MSL1, and ING4 in
total leukocytes from a separate cohort of 20 healthy
controls and 80 AAV patients (Additional file 2: Table
S2). The patients were divided evenly into MPO-ANCA
Table 1 Differentially expressed genes in patients with ANCA-associated vasculitis compared to healthy controls regulating histone
post-translational modifications and DNA methylation
Gene symbol Fragment name Entrez gene name ANCA/HC p ANCA/HC fold change
Histone H4K16, H4K5, H4K12 acetylation
MSL3 207551_s_at male-specific lethal 3 homolog 0.0002 1.65
MSL1 224765_at male-specific lethal 1 homolog <0.0001 1.60
KAT8 221820_s_at lysine acetyltransferase 8 0.0187 1.38
BRD4 226052_at bromodomain containing 4 0.0003 1.38
ING4 218234_a inhibitor of growth family, member 4 <0.0001 −2.05
Histone H3K4 methylation
MLL3 222415_at myeloid/lymphoid or mixed-lineage leukemia 3 <0.0001 1.53
MLL2 231974_at myeloid/lymphoid or mixed-lineage leukemia 2 0.0003 1.51
MLL4 203419_at myeloid/lymphoid or mixed-lineage leukemia 4 0.0107 1.26
RTF1 212302_at Rtf1, Paf1/RNA polymerase II complex component 0.0409 1.24
BCOR 223566_s_at BCL6 corepressor <0.0001 −1.74
KDM1A 212348_s_at lysine-specific demethylase 1A 0.0002 −1.57
C14orf169 219526_at lysine-specific demethylase NO66 0.0002 −1.34
Histone H3K14 acetylation
BRD4 226052_at bromodomain containing 4 0.0003 1.38
Histone H3K36 methylation
NSD1 225654_at nuclear receptor binding SET domain protein 1 0.0208 1.34
BCOR 223566_s_at BCL6 corepressor <0.0001 −1.74
C14orf169 219526_at lysine-specific demethylase NO66 0.0002 −1.34
Histone H3K9 methylation
EHMT1 222873_s_at euchromatic histone-lysine N-methyltransferase 1 0.0084 −1.41
EHMT2 202326_at euchromatic histone-lysine N-methyltransferase 2 0.0013 −1.44
ARID4B 212591_at AT rich interactive domain 4B (RBP1-like) <0.0001 −1.51
Histone H4K20 methylation
ARID4B 212591_a AT rich interactive domain 4B (RBP1-like) <0.0001 −1.51
DNA methylation
DNMT1 201697_s_at DNA (cytosine-5-)-methyltransferase 1 <0.0001 −2.03
Yang et al. Clinical Epigenetics  (2016) 8:85 Page 3 of 13
and PR3-ANCA serotypes, and each ANCA serotype
was divided into 20 remission patients (BVAS = 0) and
20 active patients (BVAS ≥ 3). Quantitative RT-PCR re-
vealed that EHMT1, EHMT2, and ING4 were statistically
reduced in leukocytes from AAV patients (n = 80) com-
pared to healthy controls (n = 20). MSL1 was statistically
elevated in AAV patients (Fig. 2a). As observed previ-
ously, in this set of patient samples, expression of MPO
and PRTN3 was highly correlated. Expression levels of
EHMT1, EHMT2, and ING4 negatively and MSL1 posi-
tively correlated with PRTN3 (ANCA 351.38 ± 608.75
versus HC 10.01 ± 8.98, p < 0.0001) and MPO (ANCA
643.41 ± 1106.44 versus HC 36.83 ± 18.27, p < 0.0001)
mRNA levels (Table 2). These data suggest an associ-
ation exists between genes that regulate histone modi-
fications linked to transcriptional status and the
expression MPO and PRTN3.
This association is further supported when comparing
the expression level of EHMT1 and 2, ING4, and MSL1
in healthy controls to AAV patients with active disease
(BVAS ≥ 3) and high MPO and PRTN3 mRNA (two
standard deviations above the mean for healthy con-
trols), and AAV patients in remission (BVAS = 0) with
low MPO and PRTN3 mRNA (no different from healthy
controls). Compared to healthy controls, the expression
of EHMT1 and 2, ING4, and MSL1 changes more dra-
matically in AAV patients with active disease and ele-
vated MPO and PRTN3 mRNA than in AAV patients in
remission with low MPO and PRTN3 mRNA (Fig. 2b).
These relationships suggest that expression of genes
that regulate histone modifications is associated with
disease activity.
A recent report describes a link between steroid ther-
apy and expression changes of autoantigen genes [20];
therefore, it is conceivable that the expression differ-
ences of histone modifying genes are a response to ther-
apy. However, in the cohort of patients used to measure
expression by qRT-PCR, there is no significant difference
in the expression of the four histone-modifying genes,
EHMNT1, EHMT2, ING4, MSL1, in patients in remis-
sion and receiving corticosteroids and patients in remis-
sion receiving another therapy, or between patients in
remission receiving no therapy and patients receiving
another therapy. Only the expression of MSL1 is signifi-
cantly different (increased) in remitting patients on cor-
ticosteroids compared to remitting patients receiving no
therapy (Additional files 2 and 3: Table S2 and Figure
S1). This suggests that corticosteroid treatment alone
does not explain changes in gene expression of histone-
modifying genes.
The altered expression of the four histone-modifying
genes detected in total leukocytes raises the question of
which cell types in the peripheral blood of patients with
AAV are responsible for the differential gene expression.
To test this, we isolated RNA from purified monocytes
and neutrophils and performed qRT-PCR to measure ex-
pression of EHMT1, EHMT2, ING4, and MSL1. In gen-
eral, patients with AAV expressed less EHMT1 and
EHMT2 compared to healthy controls in both mono-
cytes and neutrophils (Fig. 3a, b, respectively). MSL1
mRNA was significantly elevated in neutrophils (Fig. 3b)
from patients compared to healthy controls, but was not
significantly elevated in monocytes (Fig. 3a). Although
the level of ING4 message in monocytes and neutrophils
tended to be lower in patients than healthy controls, the
difference was not significant. These results point to
both monocytes and neutrophils as sources of the re-
duced expression of EHMT1 and EHMT2, while the in-
creased expression of MSL1 in patients appears to occur
predominately in neutrophils.
Reduced levels of histone mark regulating transcriptional
repression in patients with ANCA-associated vasculitis
Since we found decreased expression of EHMT1 and 2,
we tested whether there is a reduction in H3K9me2 at
MPO and PRTN3 genes. Chromatin immunoprecipitation
Table 2 Correlation of expression levels of PRTN3 and MPO with genes associated with histone modifications
Microarray Quantitative RT-PCR
Gene name Correlation with PRTN3
expression
Correlation with MPO
expression
Correlation with PRTN3
expression
Correlation with MPO
expression
MPO r = 0.840
p < 0.0001
r = 0.920
p < 0.0001
EHMT1 r = −0.213
p = 0.182
r = −0.148
p = 0.357
r = −0.436
p < 0.0001
r = −0.391
p < 0.0001
EHMT2 r = −0.461
p = 0.0024
r = −0.537
p = 0.0003
r = −0.396
p < 0.0001
r = −0.400
p < 0.0001
MSL1 r = −0.463
p = 0.0006
r = −0.412
p = 0.0046
r = −0.469
p < 0.0001
r = −0.409
p < 0.0001
ING4 r = −0.515
p = 0.0023
r = −0.433
p = 0.0075
r = −0.516
p < 0.0001
r = −0.477
p < 0.0001
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(ChIP) was performed on neutrophils isolated from 15
AAV patients and 21 healthy controls (Additional file 4:
Table S3). We detected a modest but significant decrease
in the level of H3K9me2 at both the MPO and PRTN3
gene promoters in AAV patients compared to healthy
controls (Fig. 4a). At a transcriptionally silent gene in neu-
trophils, MYO-D, there was a similar enrichment for
H3K9me2 between AAV patients and healthy controls. As
described for the expression of EHMT1 and 2 com-
pared to MPO and PRTN3 expression, H3K9me2 was
more dramatically depleted at PRTN3 and MPO pro-
moter in AAV patients with active disease and high
MPO and PRTN3 mRNA compared to controls, but
in AAV patients in remission with low MPO and
PRTN3 mRNA, H3K9me2 does not differ from the
healthy controls (Fig. 5a). We detected a modest but
significant negative correlation between H3K9me2
levels at PRTN3 and MPO promoters and expression
of MPO and PRTN3 (r = −0.346, p = 0.0386 MPO prm
and MPO expression; r = −0.373, p = 0.0252 PRTN3
prm and PRTN3 expression) (Table 3). This inverse
relationship is consistent with a role for this modifi-
cation in silencing MPO and PRTN3 in mature neu-
trophils, and the H3K9me2 silencing pathway may be
disrupted in AAV patients.
Elevated levels of histone modifications regulating
transcriptional activation in patients with ANCA-
associated vasculitis
In light of our expression data, we wondered if marks
coincident with transcriptional activation were elevated
in AAV patients. Because of increased expression of
Fig. 2 Quantitative RT-PCR analysis of candidate genes in leukocytes from AAV patients and health controls. a Quantitative RT-PCR was performed on
RNA isolated from total leukocytes of AAV patients (n = 80, black ovals) and healthy controls (HC; n = 20, light gray ovals). Expression is reported as a
relative fold change for EHMT1 (ANCA 0.51 ± 0.12 versus HC 0.69 ± 0.17, p < 0.0001), EHMT2 (ANCA 0.26 ± 0.17 versus HC 0.51 ± 0.35, p < 0.0001), MSL1
(ANCA 3.07 ± 1.07 versus HC 2.16 ± 0.89, p = 0.0009), and ING4 (ANCA 0.63 ± 0.14 versus HC 0.79 ± 0.14, p < 0.0001). b AAV patients were divided into
two groups: (1) patients with active disease (BVAS≥ 3) and high expression of autoantigen genes PRTN3 and MPO (↑mRNA, black ovals, n = 40), (2)
patients in remission (BVAS = 0) and low expression of autoantigen genes PRTN3 and MPO (↓mRNA, gray ovals, n = 40). Expression comparing AAV
patients with active disease and AAV patients in remission is reported as a relative fold change for EHMT1 (↑mRNA 0.47 ± 0.11 versus ↓mRNA 0.54 ±
0.11, p = 0.0172), EHMT2 (↑mRNA 0.22 ± 0.17 versus ↓mRNA 0.29 ± 0.15, p = 0.0074), MSL1 (↑mRNA 3.49 ± 1.07 versus ↓mRNA 2.64 ± 0.91, p = 0.0004),
and ING4 (↑mRNA 0.57 ± 0.14 versus ↓mRNA 0.69 ± 0.11, p < 0.0001). (Note: the median expression value is represented by the line in the box of the
box and whisker plot, while mean ± standard deviation is listed in figure legend)
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MSL1 (encoding a histone H4 HAT) in AAV patients,
we used ChIP to examine the level of H4K16 acetyl-
ation (H4K16ac) at MPO and PRTN3 promoters.
H4K16ac was significantly elevated in patients (n = 25)
compared to healthy controls (n = 20), but not differ-
ent between patients and controls at the FCGR3B
gene (Fig. 4b). The level of H4K16ac at the PRTN3
promoter showed a modest correlation with PRTN3
expression (r = 0.303, p = 0.0563), and H4K16ac at the
MPO promoter showed a modest, significant correl-
ation with MPO expression (r = 0.427, p = 0.0058)
(Table 3). Similar to the relationship described above
for the level of H3K9me2 and MPO and PRTN3 ex-
pression, the level of H4K16ac was markedly higher
in AAV patients with active disease and high MPO
and PRTN3 expression versus patients in remission
with low MPO and PRTN3 expression (Fig. 5b).
Because genes involved in H3 acetylation were in-
creased in AAV patients (Table 1), we performed
ChIP for H3K9,14ac. Low levels of this modification
were detected at PRTN3 and MPO promoters and not
different between AAV patients and healthy controls
(Additional file 5: Figure S2a). This was surprising
given that preliminary data that indicated H3K9,14ac
levels were closely associated with expression of MPO
and PRTN3 in HL60 cells (Additional file 5: Figure
S2b); however, this underscores the idea that regula-
tory mechanisms for the same genes may differ in cell
lines compared to primary human cells.
Several mixed-lineage leukemia genes (MLL2, 3,
and 4) were expressed more in AAV patients com-
pared to healthy controls. Since the MLLs regulate
transcriptional activation and catalyze methylation of
H3K4, we measured H3K4me2 levels. ChIP for
H3K4me2 revealed that PRTN3 and MPO promoters
were highly enriched for this modification in both
AAV patients (n = 8) and healthy controls (n = 9)
(Fig. 4c). Because the promoters of MPO and PRTN3
in healthy controls have high levels (slightly higher
than the promoters in ANCA patients) of H3K4me2,
these genes may be in a transcriptionally competent
state, ready to respond at the transcriptional level to
stimuli, but are maintained silent by repressive his-
tone modifications. Figure 5c summarizes the ChIP
data for three different histone modifications and il-
lustrates an epigenetic signature at MPO and PRTN3
genes related to disease status and autoantigen
expression.
Fig. 3 Quantitative RT-PCR analysis of candidate genes in purified monocytes and neutrophils from AAV patients and health controls. a Quantitative
RT-PCR was performed on RNA isolated from monocytes of AAV patients (n = 10, black ovals) and healthy controls (HC; n = 15, light gray ovals).
Expression is reported as a relative fold change for EHMT1 (ANCA 0.55 ± 0.08 versus HC 0.63 ± 0.09, p = 0.0213), EHMT2 (ANCA 0.88 ± 0.19 versus HC
1.15 ± 0.35, p = 0.0043), MSL1 (ANCA 0.21 ± 0.07 versus HC 0.25 ± 0.07, p = 0.192), and ING4 (ANCA 0.64 ± 0.12 versus HC 0.80 ± 0.29, p = 0.102).
b Quantitative RT-PCR was performed on RNA isolated from neutrophils of AAV patients (n = 12, black ovals) and healthy controls (HC; n = 15,
light gray ovals). Expression is reported as a relative fold change for EHMT1 (ANCA 0.80 ± 0.22 versus HC 0.95 ± 0.21, p = 0.0481), EHMT2 (ANCA
0.28 ± 0.16 versus HC 0.40 ± 0.13, p = 0.0043), MSL1 (ANCA 3.35 ± 0.74 versus HC 2.55 ± 0.63, p = 0.0157), and ING4 (ANCA 0.98 ± 0.19 versus HC
1.08 ± 0.18, p = 0.180). (Note: the median expression value is represented by the line in the box of the box and whisker plot, while mean ±
standard deviation is listed in figure legend)
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Discussion
Differential expression of genes encoding histone-
modifying enzymes
We explored whether patients with AAV had changes in
expression of genes encoding factors that establish and
maintain chromatin modifications. Analysis of microarray
data comparing AAV patients to healthy controls revealed
a network of genes related to chromatin modifications.
Quantitative RT-PCR confirmed differential expression of
EHMT1/GLP and EHMT2/G9a, encoding H3K9 methyl-
transferases, and MSL1 and ING4, encoding H4K16 ace-
tyltransferases. The expression of these four genes
correlated with expression of MPO and PRTN3, and the
expression of MPO and PRTN3 is strongly correlated.
Fig. 4 Chromatin immunoprecipitation (ChIP)-quantitative PCR analysis for histone modifications at autoantigen genes in AAV patients and healthy
controls. a ChIP-qPCR was performed on AAV patients (ANCA, black triangles, n = 15) and healthy controls (HC; gray triangles, n = 21) for H3K9me2. The
level of the H3K9me2 modification is reported as relative percent of input at the PRTN3 promoter (ANCA 12.44 ± 22.10, HC 21.17 ± 28.55; p = 0.0192),
MPO promoter (ANCA 11.37 ± 19.01, HC 20.01 ± 28.55; p = 0.0247), and a control gene, MYO-D (ANCA 21.42 ± 28.78, HC 23.63 ± 35.53; p = 0.702).
b ChIP-qPCR for H4K16ac was performed on AAV patients (ANCA, black triangles, n = 25) and healthy controls (HC; gray triangles, n = 20). The level of
the H4K16ac modification is reported as relative percent of input at the PRTN3 promoter (ANCA 17.10 ± 9.14, HC 10.83 ± 2.73; p = 0.0116), MPO
promoter (ANCA 30.30 ± 12.89, HC 21.06 ± 6.67; p = 0.0132) and at a control gene, FCGR3B (ANCA 9.19 ± 4.74, HC 8.83 ± 5.14, p = 0.864). c ChIP-qPCR for
H3K4me2 was performed on AAV patients (ANCA, black triangles, n = 8) and healthy controls (HC, gray triangles, n = 8). The level of the H3K4me2
modification is reported as relative percent of input at the PRTN3 promoter (ANCA 50.68 ± 18.15, HC 63.78 ± 32.86, p = 0.532), MPO promoter (ANCA
24.17 ± 14.80, HC 36.09 ± 18.88, p = 0.136), and at a control gene, FCGR3B (ANCA 74.01 ± 30.26, HC 82.74 ± 46.52, p = 0.878) (Note: the level of the
indicated histone modification was calculated using raw Ct values from qPCR of diluted input sample. The median expression value is represented by
the line in the box of the box and whisker plot, while mean ± standard deviation is listed in figure legend)
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Furthermore, expression of EHMT1 and 2, MSL1 and
ING4 differed more between healthy controls and AAV
patients with active disease (BVAS ≥ 3) and the highest
levels of MPO and PRTN3 mRNA than between healthy
controls and AAV patients in remission (BVAS = 0) with
low levels ofMPO and PRTN3 mRNA.
Fig. 5 ChIP-quantitative PCR analysis for histone modifications at autoantigen genes in ANCA-patients with high and low PRTN3 and MPO expression.
a The level of H3K9me2 is reported as relative percent input for AAV patients with active disease (BVAS≥ 3) and high expression of PRTN3 and MPO
(↑mRNA, black triangles, n = 7) and for healthy controls (HC; light gray triangles, n = 21) at the PRTN3 promoter (↑mRNA 3.41 ± 5.20, HC 21.17 ± 28.55; p
= 0.0068) and the MPO promoter (↑mRNA 3.34 ± 6.02, HC 20.01 ± 26.00; p = 0.0058). The level of H3K9me2 is reported as relative percent input for AAV
patients in remission (BVAS = 0) and low expression of PRTN3 and MPO (↓mRNA, gray triangles, n = 8) for healthy controls at the PRTN3 promoter
(↓mRNA 20.33 ± 28.30, HC 21.17 ± 28.55; p = 0.294) and at the MPO promoter (↓mRNA 18.41 ± 23.88, HC 20.01 ± 26.00; p = 0.393). b The level of
H4K16ac is reported as relative percent input for AAV patients with active disease (BVAS≥ 3) and high expression of PRTN3 and MPO (↑mRNA, black
triangles, n = 17) and for healthy controls (HC; light gray triangles, n = 20) at the PRTN3 promoter (↑mRNA 19.12 ± 9.31, HC 10.83 ± 2.73; p = 0.0009) and
the MPO promoter (↑mRNA 33.26 ± 11.03, HC 21.56 ± 6.67; p = 0.0006). The level of H4K16ac is reported as relative percent input for AAV patients in
remission (BVAS = 0) and low expression of PRTN3 and MPO (↓mRNA, gray triangles, n = 8) for healthy controls at the PRTN3 promoter (↓mRNA 12.81 ±
7.55, HC 10.83 ± 2.73; p = 0.939) and at the MPO promoter (↓mRNA 24.02 ± 15.02, HC 21.56 ± 6.67; p = 0.859). (Note: the level of the indicated histone
modification was calculated using raw Ct values from qPCR of diluted input sample. The median expression value is represented by the line in the box
of the box and whisker plot, while mean ± standard deviation is listed in figure legend.) c Illustration depicts a model for modifications of histone tails
at promoters of PRTN3 and MPO in healthy controls and AAV patients in remission (top), and in AAV patients with active disease (bottom)
Yang et al. Clinical Epigenetics  (2016) 8:85 Page 8 of 13
Histone modifications at autoantigen genes associated
with disease activity
We also explored in patients with AAV whether the
histone modifications regulated by these differentially
expressed genes were altered at MPO and PRTN3 genes.
In neutrophils from patients with high MPO and PRTN3
mRNA and active disease, the MPO and PRTN3 pro-
moters were depleted for H3K9me2 and enriched for
H4K16ac compared to healthy controls and patients in
remission. In contrast, another histone modification that
is associated with gene activation showed similar levels be-
tween AAV patients and healthy controls (H3K9,14ac),
while H3K4me2 levels were enriched at MPO and PRTN3
in patients and healthy controls. These data and our previ-
ous ChIP studies on neutrophils demonstrate that MPO
and PRTN3 genes in healthy controls and AAV patients in
remission are enriched for silencing marks H3K27me3
and H3K9me2 and the activation mark H3K4me2. In con-
trast, MPO and PRTN3 genes in active AAV patients have
reduced levels of H3K27me3 and H3K9me2, maintain en-
richment of H3K4me2, and gain the activation mark
H4K16ac.
Two results from the expression analysis were un-
expected. First, we did not identify changes in gene
expression in AAV patients for genes encoding Poly-
comb Repressor Complex-2 (PRC2) subunits. How-
ever, the absence of changes in PRC2 genes is
consistent with a model we proposed in which the
deficit in H3K27me3 genes results from a failure to
recruit PRC2 to MPO and PRTN3 via RUNX3, or his-
tone demethylase activity [15]. Second, although our
initial measurements of H3K9me2 showed a modest
decrease in AAV patients, we found reduced expres-
sion of EHMT1/GLP and EHMT/G9a in patients. Re-
examining the ChIP data for H3K9me2 revealed the
modification was more dramatically depleted at MPO
and PRTN3 in active AAV patients with high autoan-
tigen gene expression. This suggests that in addition
to H3K27me3, H3K9me2 and the factors that catalyze
this histone mark contribute to the transcriptional
silencing of ANCA autoantigen genes in healthy indi-
viduals and AAV patients in remission.
H3K27me3 and H3K4me2 enriched at autoantigen genes
in PMNs from healthy individuals and AAV patients in
remission
The levels of both H3K27me3 and H3K4me2 at MPO
and PRTN3 genes raises the intriguing possibility that in
healthy controls and remitting patients, these genes are
maintained in a bivalent epigenetic state. A model to ex-
plain the function of this chromatin state proposes that
bivalent genes are suppressed in pluripotent cells but
poised for activation later in development [21, 22].
Genome-wide chromatin studies have detected bivalent
domains in differentiated cells, particularly of the
hematopoietic lineage [23, 24]. An exciting possibility is
that in peripheral blood neutrophils, the PRTN3 and
MPO genes adopt a bivalent mode of transcriptional
control and exist as transcriptionally poised genes. Al-
though a poised chromatin state is consistent with stud-
ies demonstrating inducible transcriptional activity in
neutrophils [25–29], it is possible that the apparent bi-
valent signature represents a mosaic between neutro-
phils with H3K27me3 and neutrophils with H3K4me2. If
a population of neutrophils contains a mixture of cells
with either one of these two histone modifications, it
would suggest that neutrophils with H3K4me2 employ
another silencing mechanism; distinguishing these possi-
bilities warrants further investigation.
Other potential cell types responsible for differential
expression of autoantigen genes
The model of epigenetic control we propose assumes
that the elevated expression of MPO and PRTN3 in
AAV is primarily from neutrophils. Others have re-
ported increased MPO and PRTN3 expression in
monocytes, myeloid progenitors, or low density gran-
ulocytes [30–32]. This could explain the moderate
correlations we observe between MPO and PRTN3
expression from total leukocytes and histone modifi-
cations at MPO and PRTN3 in purified neutrophils.
Evidence from in situ hybridization [13] and compari-
son of expression with differential blood counts
(manuscript in preparation) indicates AAV patients
have increased expression of MPO and PRTN3 in per-
ipheral neutrophils, but this does not exclude the
contribution of other cell types to MPO and PRTN3
expression. Indeed, the differential expression of
chromatin-modifying factors was identified in total
leukocytes; therefore, it is possible that altered expres-
sion of these factors in patients with AAV could
occur in other peripheral blood cells. We identified
differential expression of EHMT1, EHMT2, and MSL1
in neutrophils, but we also detected reduced levels of
EHMT1 and EHMT2 in monocytes. The increased ex-
pression of MSL1 in neutrophils of patients with AAV
is consistent with the elevated levels of H4K16ac we
Table 3 Correlation of PRTN3 and MPO expression with
H3K9me2 and H4K16ac levels at PRTN3 and MPO promoter
H3K9me2 (N = 36) H4K16ac (N = 40)
Gene name Correlation
with PRTN3
expression
Correlation
with MPO
expression
Correlation
with PRTN3
expression
Correlation
with MPO
expression
PRTN3 promoter r = −0.373
p = 0.0252
r = −0.303
p = 0.0563
MPO promoter r = −0.346
p = 0.0386
r = −0.427
p = 0.0058
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detected at MPO and PRTN3 in neutrophils from patients
with active disease. Intriguingly, monocytes, which did not
differentially expression MSL1 between patients and
healthy controls, may regulate transcriptional activation
through a different network of epigenetic regulators. Low
density granulocytes could also have altered expression of
these histone-modifying genes.
By extension, the pattern of histone modifications we
identified in neutrophils at MPO and PRTN3 might
occur in other cell types. In fact, publically available data
from the Encyclopedia of DNA Elements (ENCODE)
project corroborates enrichment of H3K4me2 at the
promoter and within the gene body of PRTN3 and MPO.
Conversely, very little enrichment of H3K27me3 at MPO
and PRTN3 is reported for monocytes. Depending on
the cell type, the transcriptional output of these autoan-
tigen genes in patients with active AAV may use similar
but not identical chromatin regulatory mechanisms. In-
vestigating epigenetic patterns of other myeloid lineages
would further define transcriptional regulatory mecha-
nisms during AAV.
Heterogenous surface PR3 expression among neutrophils
We report the level of specific histone modifications at
autoantigen genes in samples of total circulating neutro-
phils; however, several reports have documented a subset
of neutrophils with membrane bound PR3 (mPR3) and
the surface glycoprotein CD177. The fraction of neutro-
phils positive for mPR3 and surface CD177 ranges from
0 to 100 %, is genetically determined and stable, and is
elevated in patients with AAV [33–36]. It is conceivable
that this subset of neutrophils could influence the level
of a particular histone modification measured at autoan-
tigen genes. For instance, the observation that histone
modifications are more dramatically altered in patients
with increased expression might also reflect patients
with a larger percentage of mPR3 and CD177 positive
neutrophils. However, separate reports have described
conflicting results on whether mPR3 and CD177 positive
neutrophils have elevated PRTN3 expression [37, 38];
thus, the association of a histone modification signature
with increased autoantigen expression may not depend
on mPR3 and surface CD177 positivity. In addition,
PR3-ANCA has been shown to stimulate neutrophil ac-
tivation regardless of mPR3 status [39]. This is consist-
ent with the hypothesis that dysregulation of neutrophil
transcriptional status, likely the result of epigenetic
changes, predisposes neutrophils to activation.
Limitations of current epigenetic analysis, and rationale
for future epigenomic studies in patients with AAV
Although the role epigenetic mechanisms play in AAV
and other vasculitides is being investigated more inten-
sively [40], challenges still remain. For instance, this
study does not distinguish whether or not epigenetic
changes are a consequence of AAV or are an integral
component of AAV pathogenesis, and our patient sam-
ples prevented an investigation of the role of therapy on
the chromatin status. However, our results provide a ra-
tionale for further investigating the role of epigenetic
changes in AAV. Measuring the status of histone modifi-
cations longitudinally will more accurately assess the re-
lationship of a histone signature with disease status.
Genome-wide mapping of histone modifications will de-
fine chromosomal domains and genes within those
domains with shared regulatory mechanisms. This is
critical to identify potential chromatin regulatory net-
works that play a role in neutrophil activation in AAV.
Coupled with data from genome-wide association stud-
ies epigenomic profiling in AAV, especially expanded to
include other cell types, will inform potential function of
genetic variants [41].
Conclusions
While additional questions remain to be answered, the
close association of specific histone modifications with
active AAV is consistent with the hypothesis that an epi-
genetic signature corresponds to disease status, and sug-
gests that a dynamic epigenome is involved in the
pathogenesis of AAV. Thus, in addition to the presence
of autoantibodies, the plasticity of the epigenome may
promote the development of AAV.
Methods
Patients
Patients with biopsy-proven anti-neutrophil cytoplasmic
autoantibody (ANCA) systemic vasculitis or renal-
limited disease enrolled in this study were diagnosed be-
tween 1985 and 2013 and followed in the Glomerular
Disease Collaborative Network (GDCN) [42, 43]. All
study materials were given Institutional Review Board
approval for human subjects (IRB study #97-0523) by
the University of North Carolina Office of Human Re-
search Ethics. Study subjects gave informed, written con-
sent and participated according to UNC IRB guidelines.
A total of 122 patients with ANCA vasculitis and 71
healthy controls were included in this study. Patients
were diagnosed according to the Chapel Hill Consensus
Conference [44, 45]. ANCA serotypes were determined
by indirect immunofluorescence and/or antigen-specific
proteinase (PR3) and myeloperoxidase (MPO) enzyme-
linked immune-absorbent assays (ELISA) [46]. Disease
activity was determined using the 2003 Birmingham
Vasculitis Activity Score (BVAS) [47]. Remission was de-
fined as BVAS = 0 and no clinical or laboratory evidence
of active disease, and active disease was defined as a
BVAS ≥ 3 with clinical and/or laboratory evidence of dis-
ease. Among the ANCA cohort, 25 samples from 21
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patients were enrolled in a microarray study listed in
Additional file 1: Table S1, 80 samples from 80 patients
in a quantitative PCR study of total leukocytes listed in
Additional file 2: Table S2, 22 samples (10 monocytes
and 12 neutrophils) from 13 patients in a quantitative
PCR study of purified cell types listed in Additional
file 2: Table S2 (samples TM81-TM93), and 32 sam-
ples from 32 patients in several chromatin immuno-
precipitation studies listed in Additional file 4: Table
S3 and Additional file 6: Table S4. The tables in these
Additional files include the following information for
each patient: race, gender, age, diagnosis, ANCA
subtype, disease status, BVAS, ANCA titer, serum cre-
atinine, and treatment, WBC counts, and absolute
neutrophil counts, if available.
Microarray and quantitative RT-PCR
RNA from circulating leukocytes was extracted using
RNA STAT-60 (Tel-Test “B”, Friendswood, TX, USA) and
DNase treated. For the microarray study, 25 ANCA-
patient samples were compared to 16 healthy controls by
Affymetrix microarray gene chip for identification of gene
expression levels, as previously described [13, 15, 48]. Dif-
ferentially expressed genes were identified by analysis of
variance (ANOVA) using Partek Genomics Suite (Partek
GS 6.4, St Louis, CA) with a 1.2-fold change and p value
<0.05 between patient and healthy control groups. Differ-
entially expressed genes were analyzed using the Ingenuity
Pathway Analysis (IPA; Java version 1.7.0_25 and 1.6.0_51;
Ingenuity Systems, Redwood City, CA) to evaluate bio-
logical themes [49].
For quantitative RT-PCR, leukocyte RNA was analyzed
from 40 PR3-ANCA patients and 40 MPO-ANCA pa-
tients (each group of 40: remission (BVAS = 0), n = 20;
active (BVAS ≥ 3), n = 20), and 20 healthy controls.
Quantitative detection of MPO and PRTN3 mRNA levels
from patient samples was determined using a standard
curve. The standard curve for MPO mRNA levels was
generated using HL60 cells, a cell positive for MPO
mRNA, diluted with Jurkat cells, a cell line negative for
MPO mRNA. The standard curve for PRTN3 mRNA
levels was generated using THP-1 cells, a cell positive
for PTRN3 mRNA, diluted with Jurkat cells, a cell line
negative for PRTN3 mRNA. MPO and PRTN3 mRNA
levels for patients and healthy donor samples were de-
termined by 2−ΔΔCt calculations and expressed relative
to standard curves. Primers and probes for MPO and
PRTN3 were previously published, and Cytochrome c
oxidase (COX5B) was used as mRNA internal control
[13]. Quantitative detection of EHMT1/GLP, EHMT2/
G9a, MSL1, and ING4 mRNA levels was determined by
2−ΔΔCt calculations, with COX5B as the mRNA internal
control, and expressed as fold change of reference con-
trol samples. Primers and probes were purchased from
Applied Biosystems (Applied Biosystems, Foster City,
CA). Quantitative RT-PCR assays were performed on an
ABI PRISM 7900HT sequence detection system (Applied
Biosystems), using the TaqMan EZ RT-PCR kit (Applied
Biosystems).
Monocyte and neutrophil isolation
Peripheral blood was collected in two 10 ml sodium
heparin tubes (14–18 ml of blood). Red blood cells
were depleted with 1 volume HetaSep (Stem Cell
Technologies) for 5 volumes whole blood and centri-
fuged at 92g, 6 min, no brake. The nucleated cells
were layered on Histopaque 1077 (Sigma) and centri-
fuged (400g, 30 min, no brake). PBMCs were washed
once with PBS before isolating cell types using mag-
netic microbeads. CD14+ monocytes were isolated
with the Human CD14 Positive Selection Kit as previ-
ously described (EasySep™, Stem Cell Technologies)
[50, 51]. RNA was extracted from monocytes with the
Qiagen AllPrep DNA/RNA Mini Kit (Qiagen, Chats-
worth, CA). In parallel, neutrophils were isolated
from the red blood cell/granulocyte pellet remaining
after the Histopaque spin. The neutrophil pellet was
washed once with PBS, and red cells were lysed with
5 ml water followed by 5 ml 2× PBS. Neutrophils
were pelleted (300g, 10 min), lysed with STAT-60
(Tel-Test “B”, Friendswood, TX, USA), and RNA was
extracted.
Chromatin immunoprecipitation (ChIP)
ChIP for H3K9me2 was previously described [15]. ChIP
for H4K16ac and H3K4me2 followed a similar proced-
ure with the following modifications: neutrophils were
isolated by HetaSep (StemCell Technologies, Vancou-
ver, BC, Canada). Cells (5 × 106 cells/ml/sample) were
incubated with formaldehyde at a final concentration of
0.6 % to crosslink DNA and proteins, and then lysed
and sonicated in lysis buffer without SDS (10 mM Tris-
HCl, pH 8.0; 100 mM NaCl; 1 mM EDTA, pH 8.0;
0.5 mM EGTA; 0.1 % Na-Deoxycholate; 0.5 % N-Laur-
oylsarcosine). After sonication, lysate was diluted 1:1 in
lysis buffer and Triton X-100 was added to 1 % final
concentration. Anti-H3K9me2 antibody was purchased
from Abcam (Abcam, Cambridge, MA), and anti-
H3K4me2, H4K16ac, and H3K9,14ac antibodies from
Millipore (EMD Millipore, Billerica, MA). Primers for
Q-PCR of PRTN3 and MPO promoter regions and con-
trol MYO-D were previously published [15]. FCGR3B
promoter, sense primer (CCACCATAGAACAGGAAT
AG) and antisense primer (AGACCTTTGGGAGAGT
AAA) were from Integrated DNA Technologies (Inte-
grated DNA Technologies, Coralville, IA). Specific
DNA was analyzed by quantitative PCR and expressed
as a relative percent of input chromatin. The level of
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enrichment for the indicated histone modification was
calculated using raw Ct values from qPCR of diluted
input sample.
Statistics
Descriptive statistics include mean and standard devi-
ation, or median and interquartile range for non-normal
distributions. Differences between two groups were
compared by Wilcoxon test. Spearman rank correlations
were used. Analyses and plots were conducted with SAS
software (Version 9.3) (SAS Institute, Cary, NC). Micro-
array data was analyzed by ANOVA using Partek GS 6.4.
Dot plots and box and whisker plots in each figure were
generated by Partek GS 6.4.
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